Author

Jean Engels

Observed names: J. Engels, Jean M Engels, Jean M. Engels

Institution: Tonix Pharmaceuticals (United States)

Observed institutions: Hospital for Sick Children, Ruhrlandklinik, Tonix Pharmaceuticals (United States), University of Duisburg-Essen

ORCID: 0009-0008-0098-5133

Observed ORCID: 0009-0008-0098-5133

OpenAlex ID: A5032437529

Denufosol: A review of studies with inhaled P2Y2 agonists that led to Phase 3

2008 · Donald Kellerman, Andrea Rossi Mospan, et al. · Pulmonary Pharmacology & Therapeutics · 101

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

2005 · Robin Deterding, George Retsch‐Bogart, et al. · Pediatric Pulmonology · 92

Phase 2 Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis

2007 · Robin R. Deterding, Lisa M. LaVange, et al. · American Journal of Respiratory and Critical Care Medicine · 91

Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine

2025 · Seth Lederman, Lesley M Arnold, et al. · Pain Medicine · 21

Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response

2021 · Gregory M. Sullivan, R. Michael Gendreau, et al. · Psychiatry Research · 17

A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder

2024 · Megan E. Parmenter, Seth Lederman, et al. · Psychiatry Research · 10

47 Denufosol tetrasodium inhalation solution: results from two phase 2 trials in CF patients with mild to moderate lung disease

2006 · L. Smiley, A. Rossi, et al. · Journal of Cystic Fibrosis · 5

Pooled Efficacy from Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Patients with Fibromyalgia

2026 · Errol Gould, Seth Lederman, et al. · Pain Management Nursing · 1

Pos0324 Targeting Non-restorative Sleep in Fibromyalgia With Bedtime Tnx-102 Sl (sublingual Cyclobenzaprine Hcl) Significantly Improves Pain in Resilient, a Confirmatory Phase 3 Randomized Clinical Trial

2024 · I. Iglehart, S. Lederman, et al. · Annals of the Rheumatic Diseases · 1

Onset of Action of a Zolmitriptan Microneedle System (M207, Qtrypta™) for Migraine: Comparison with Recent Early Time to Onset Recommendations, Pain Relief Results and Placebo Response (1977)

2021 · Deborah Friedman, Egilius Spierings, et al. · Neurology · 1

Comparison of Efficacy Outcomes in Trials Using a M207 in the Acute Treatment of a Single Migraine or Multiple Migraines (2136)

2021 · Donald Kellerman, Jean Engels · Neurology · 1

854. Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 Sl in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response

2017 · Gregory Sullivan, Judith Gendreau, et al. · Biological Psychiatry · 1

TNX-102 SL, Cyclobenzaprine Hydrochloric Acid Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia

2026 · Seth Lederman, Gregory M. Sullivan, et al. · Journal of Pain

47 Reactive airway disease and cystic fibrosis: a retrospective analysis of the safety and tolerability with denufosol inhalation solution

2007 · A. Rossi, V. Brandi, et al. · Journal of Cystic Fibrosis

Works count: 14

Citation count: 342

H-index: 6

I10-index: 6